# US 2020/0393472 A1 · Haemoglobin analysis method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0393472 A1
- Document ID: US20200393472A1
- Status: Published application
- Kind: A1
- Application number: 16/971,393
- Filed: 2019-04-18
- Published: 2020-12-17
- Earliest claimed: 2018-04-18
- Assignees: Sekisui Medical Co., Ltd.
- Applicants: Sekisui Medical Co., Ltd.
- Inventors: Hiroaki TAIRA; Ei-ichiro SUNAMURA; Kohei MATSUDA; Takuya YOTANI
- Web page: https://patentgrep.com/patent/US20200393472A1

## CPC

- G01N 30/88: Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N 33/721: {Haemoglobin}
- G01N 30/02: Column chromatography
- G01N 30/96: using ion-exchange (G01N30/02, G01N30/90 take precedence)
- G01N 30/34: of fluid composition, e.g. gradient (G01N30/36 takes precedence)
- G01N 2030/067: {by reaction, e.g. derivatising the sample}
- G01N 2030/8822: {involving blood}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided is a method for separating and detecting various hemoglobins including abnormal hemoglobins and thalassemia markers. A method for analyzing hemoglobins, comprising separating hemoglobins in a sample by cation exchange chromatography, wherein an eluent having a pH of 8.1 or more and an osmotic pressure of 40 mOsm/kg or less is used for separation of the hemoglobins.

## Claims

### Claim 1

A method for analyzing hemoglobins, comprising
separating hemoglobins in a sample by cation exchange chromatography,
wherein an eluent having a pH of 8.1 or more and an osmotic pressure of 40 mOsm/kg or less is used for separation of the hemoglobins.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the eluent comprises a buffer without metal ions.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the buffer is Bicine, Tricine or TES.

### Claim 4 (depends on 2)

The method according to claim 2, wherein a concentration of the buffer in the eluent is 2 to 17 mmol/L.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the eluent comprises a hemoglobin denaturing agent.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the hemoglobins are separated by gradient elution using the eluent.

### Claim 7 (depends on 6)

The method according to claim 6, wherein a proportion of the eluent in the gradient increases from 0% to 100%.

### Claim 8 (depends on 1)

The method according to claim 1, wherein at least one abnormal hemoglobin selected from the group consisting of HbS, HbC, HbE, HbD, and HbO-Arab is separated.

### Claim 9 (depends on 1)

The method according to claim 1, wherein at least one thalassemia marker selected from the group consisting of HbA2, HbF, HbH, Hb Bart′, and Hb Constant Spring is separated.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the chromatography is high performance liquid chromatography.

### Claim 11

An eluent, having a pH of 8.1 or more and an osmotic pressure of 40 mOsm/kg or less.

### Claim 12 (depends on 11)

The eluent according to claim 11, wherein the eluent comprises a buffer without metal ions.

### Claim 13 (depends on 12)

The eluent according to claim 12, wherein the buffer is Bicine, Tricine or TES.

### Claim 14 (depends on 12)

The eluent according to claim 12, wherein a concentration of the buffer in the eluent is 2 to 17 mmol/L.

### Claim 15 (depends on 11)

The eluent according to claim 11, wherein the eluent comprises a hemoglobin denaturing agent.

### Claim at position 16

16-21 (canceled)
